AstraZeneca expands its Global Medicines Development (GMD) Centre in India
31st May 2018: Global science-led biopharmaceutical company AstraZeneca officially opened its new Global Medicines Development (GMD) Centre in Bengaluru, India today. This unit is one of AstraZeneca’s nine GMD centres around the world that transform breakthrough molecules into medicines and monitor their use and safety. With this opening, India will now play an even bigger role in AstraZeneca’s global operations.
Globally,GMD works with AstraZeneca’s two biotech units – Innovative Medicines and EarlyDevelopment (IMED) and MedImmune – and the Global Portfolio and ProductStrategy (GPPS) organisation to understand where there is unmet medical need,to shape AstraZeneca’s therapy area strategies from early development throughto commercialisation.
The GMDBengaluru team will focus on supporting AstraZeneca’s medicines, which coverstreatments across a range of therapy areas, including oncology, respiratory andcardiovascular and metabolic diseases. GMD Bengaluru plays a key rolesupporting 51 of AstraZeneca’s mature brands which are used by patients aroundthe world. During the last year, the team has recruited scientific experts inthe fields of regulatory science, clinical, and patient safety, and has grownfrom 30 to 70 people. The expansion will see a further increase to more than100 specialists.
HisExcellency Klas Molin, Swedish Ambassador to India and Chief Guest for theinauguration stated, “Further to the bilateral innovation partnership betweenIndia and Sweden, we are pleased to bring more Swedish innovation into thecountry. The opening of AstraZeneca GMD unit in India is yet another promisingstep for strengthening this partnership for a sustainable future between Swedenand India.”
Ms.Elisabeth Björk VP, Global Medicines Development Unit Head for Cardiovascular,Metabolic Renal Diseases, AstraZeneca present at the inauguration of the newGMD office space in Bengaluru said, “AstraZeneca has a long-standing commitmentin India over 40 years. The GMD expansion is part of AstraZeneca’s continuedcommitment to enhance scientific innovation in the country and I am delightedto open our newest GMD site and to welcome our new colleagues to theAstraZeneca team".
Ms. VeenaRajan, GMD Site Lead Bengaluru, AstraZeneca India Private Limited stated, “Weplan to recruit more physicians, scientists and regulatory experts to supportthe GMD Bengaluru, and continue to deliver value for our global mature brandsin oncology, respiratory, cardiovascular and metabolic diseases.”
Mr. SivaPadmanabhan, Centre Head, Global Technology Centre Chennai, AstraZeneca IndiaPrivate Limited said, “The GMD expansion further strengthens AstraZeneca’scommitment to invest in scientific capabilities to deliver more effectivemedicines to help meet unmet treatment needs for patients around the world.”